bs_bs_banner

Clinical and Experimental Ophthalmology 2015; 43: 214–220 doi: 10.1111/ceo.12431

Original Article Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease Ivan Goldberg AM FRANZCO FRACS,1,2,3 Stuart L Graham PhD FRANZCO,1,3,4 Jonathan G Crowston PhD FRANZCO5,6 and Guy d’Mellow FRANZCO7,8 on behalf of the Australian and New Zealand Glaucoma Interest Group 1

Discipline of Ophthalmology, University of Sydney, 2Glaucoma Unit, Sydney Eye Hospital, 3Eye Associates, 4Australian School Advanced Medicine, Macquarie University, Sydney, New South Wales, 5Department of Ophthalmology, University of Melbourne, 6 Centre for Eye Research Australia, Melbourne, Victoria, 7Terrace Eye Centre and 8Greenslopes Hospital, Brisbane, Queensland, Australia

ABSTRACT Background: Ocular surface disease (OSD) is relatively common in glaucoma patients. OSD symptoms could be linked to prolonged exposure to preservatives in anti-glaucoma medications, especially benzalkonium chloride (BAK). The OBSERVE clinical audit was designed to track the impact of intraocular pressure lowering medications in patients with evidence of OSD to test the hypothesis that BAK-free anti-glaucoma preparations offer clinical advantages over BAK-containing products. Design: Prospective clinical audit from March 2012 to April 2013, open to ophthalmologists practising in Australia. Participants: There were 375 patients enrolled, with a completion rate of 64%. The cohort was predomi-

nantly female (68%) with an average age of 71 years. Methods: Patients were screened for inclusion during a routine consultation. If eligible, they were enrolled. At the ophthalmologist’s discretion, some patients were switched to BAK-free anti-glaucoma products. Data were collected via an online survey completed by the ophthalmologist during three appointments over a 16- to 30-week period for all patients. Main Outcome Measures: Intraocular pressure, tear-film breakup time, McMonnies Dry Eye Questionnaire score and reported lubricant use. Results: Patients who switched to BAK-free preparations reported a significant fall in the use of lubricants (P = 21 Normal: 10–21 High: >21

No switch

Baseline assessment (%)

Secondary assessment (%)

Final assessment (%)

170 (87.2) 25 (12.8) 39 (84.8) 7 (15.2)

178 (91.3) 17 (8.7) 41 (89.1) 5 (10.9)

181 (92.8) 14 (7.2) 42 (91.3) 4 (8.7)

BAK, benzalkonium chloride. © 2014 Royal Australian and New Zealand College of Ophthalmologists

Eye drops and surface disease Table 2.

217

Analysis of variance for the tear film break-up time (seconds) over time

Effect

Degrees of freedom

Chi-squared

Pr > ChiSq

2 2 2

3.37 41.07 4.24

0.1855 10 s) Marginal TBUT(5−10 s)

Baseline

Figure 2. McMonnies Dry Eye Questionnaire score over time for switched cohort.

Secondary Clinical visit

Switched

Non-switched

Switched

Non-switched

Switched

Low TBUT(14.5 at baseline. There was a significant decrease in MMDEQ scores over time in both groups (P =

Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.

Ocular surface disease (OSD) is relatively common in glaucoma patients. OSD symptoms could be linked to prolonged exposure to preservatives in anti-gl...
327KB Sizes 0 Downloads 4 Views

Recommend Documents


Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
Long-term use of benzalkonium chloride (BAC)-preserved drugs is often associated with ocular surface toxicity. Ocular surface symptoms had a substantial impact on the glaucoma patients' quality of life and compliance. This study aimed to investigate

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma.
Benzalkonium chloride (BAK), included as a preservative in many topical treatments for glaucoma, induces significant toxicity and alters tear breakup time (TBUT). BAK-containing latanoprost, an ester prodrug of prostaglandin F2α, can cause ocular adv

The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye.
To test the hypothesis that benzalkonium chloride (BAK) alters the ocular surface in normal and dry eye mice and that a BAK-free commercially available antiglaucoma treatment does not induce the same effects.

The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study.
Purpose. The aim was to compare the effects of antiglaucoma eye drops on the tear functions and ocular surface. Method. Eighty-five eyes of 43 patients with glaucoma were included into this randomized prospective study. Timolol without preservative (

Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy.
To evaluate ocular surface changes and its correlation with the central corneal subbasal nerve fibre layer in chronic glaucoma patients.

Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma.
The aim of this study was to assess signs and symptoms of ocular surface disease (OSD) and the cytomorphological changes of ocular surface in glaucoma patients using preserved antiglaucoma drops.

Does the use of preoperative antiglaucoma medications influence trabeculectomy success?
To investigate the influence of preoperative antiglaucoma medications on trabeculectomy outcome.

Prosthetic replacement of the ocular surface ecosystem scleral lens therapy for patients with ocular symptoms of chronic Stevens-Johnson syndrome.
To evaluate the results of Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) scleral lens treatment on visual acuity and function in patients with ocular symptoms of chronic Stevens-Johnson syndrome (SJS).

Ocular toxicity of benzalkonium chloride homologs compared with their mixtures.
This study was performed to assess the in vivo ocular toxicity of benzalkonium chloride (BAK) homologs compared with commercially available BAK (BAK mixture) and to assess the ocular toxicity of BAK homolog after repeated ocular application. Rabbit e